Funding new drug development is challenging. Trials are expensive, complex, and lengthy, and only a fraction of the therapeutics that go into clinical trials will ever come out the other side approved. Sarah Shores welcomes Dr. Andrew Lo, economist, professor at MIT and co-founder of QLS Advisors, a Quantitative Life Sciences Company working to accelerate the pace of change in biomedicine.
Sources referenced: Stein, R. (2017) Incentivizing Charity: A New Way to Fund Cancer Research; Healthcare Finance: Modern Financial Analysis for Accelerating Biomedical Innovation by Andrew Lo, Shomesh E. Chaudhuri
Diversification does not assure a profit and may not protect against loss of principal. Diversification among investment options and asset classes may help to reduce overall volatility. Risk management and due diligence processes seek to mitigate, but cannot eliminate, risk nor do they imply low risk.
Subscribe below and explore our website:
Apple podcasts: 1blk.co/3Gvvo5q
Spotify: 1blk.co/3hZNdPU
BlackRock: blackrock.com/thebid